US v Pharma
Fighting
to Protect Medicare Negotiation
US v Pharma Fighting to Protect Medicare Negotiation
Fighting to Protect Medicare Negotiation
Patients For Affordable Drugs (P4AD) is the only national patient advocacy organization exclusively focused on lowering prescription drug prices. At the core of our mission was securing Medicare negotiation in the Inflation Reduction Act. Now, with this crucial provision under attack, our mission is clear: fight to protect Medicare negotiation.
However, Big Pharma is not going down easy. Several major drug companies have launched aggressive lawsuits seeking to dismantle the law and maintain their grip on drug pricing. These lawsuits threaten millions of patients whose drug costs are out of control and who would feel relief from Medicare negotiation.
Despite the pharmaceutical industry’s efforts and the millions of dollars they’ve invested in their cases, we’re gaining ground.
- A district judge in New Jersey rejected Novartis’ lawsuit in October.
- A district judge in Ohio dismissed the case brought by various Chambers of Commerce in August.
- A federal judge in New Jersey ruled against Bristol Myers Squibb and Janssen Pharmaceuticals in their cases in April and against Novo Nordisk in its case in July.
- A federal judge in Connecticut ruled against Boehringer Ingelheim’s legal challenge in July.
- A federal judge in Delaware ruled against AstraZeneca in its case in March.
- A federal district judge in Texas dismissed a similar lawsuit from the industry lobby Pharmaceutical Research and Manufacturers of America (PhRMA) in February.
- A district judge in Ohio ruled against the U.S. Chamber of Commerce’s case in September 2023.
That’s eight times that a judge has ruled against pharma and for patients!
As we continue to push forward, it’s clear that our efforts are making a difference. But the fight is far from over, and we need your help to ensure that patients take precedence over corporate profits.
The Impact
In August 2023, the Centers for Medicare and Medicaid Services published the first 10 drugs covered under Medicare Part D selected for negotiation. All of the drug companies that make these medications agreed to participate in negotiations, while simultaneously filing lawsuits against the federal government to stop this program from going into effect.
People on Medicare paid $3.4 billion in out-of-pocket costs for these drugs in 2022. Meanwhile, Big Pharma’s pockets were padded as they spent more on stock buybacks and dividends than they did on research and development, even as nearly three in ten people in the United States struggle to afford their medications because of cost.
On August 15th 2024, the new lower list prices negotiated by Medicare were announced. For drug by drug prices visit our Medicare Negotiation site.